Key statistics
Previous close$58.53
Open$58.50
Day high$59.44
Day low$58.12
52-week high$59.44
52-week low$34.08
Market cap25.02B
Volume2.54M
Average volume3.75M
P/E ratio11.48
Forward P/E—
EPS5.07
Dividend yield+1.56%
Market context
Why it moved
Despite Royalty Pharma declaring its third quarter 2026 dividend and recently hitting an all-time high, RPRX shares edged slightly lower as broader market selling pressure — driven by a semiconductor selloff, AI trade concerns, and general market volatility — weighed on the stock.
What is happening
Recent company-specific developments and publisher coverage.
July 17, 2026Royalty Pharma closed modestly lower, pulling back slightly from its 52-week high of $59.44 reached intraday, as the broader healthcare sector (XLV) faced pressure amid a risk-off tone driven by escalating U.S.-Iran tensions and a tech-led market selloff. Investor focus is shifting toward the company's Q2 2026 earnings release scheduled for August 5, with analysts broadly bullish — seven firms carrying Buy ratings and TD Cowen recently raising its price target to $65. Adding a near-term catalyst, Royalty Pharma's board declared its Q3 2026 dividend of $0.235 per share today, payable September 10 to shareholders of record August 14.-0.598
July 17, 2026Royalty Pharma surged nearly 4%, touching its 52-week high of $58.84 intraday, as the broader healthcare sector rallied on a wave of strong Q2 earnings from major names including UnitedHealth Group and Abbott. TD Cowen's recent price target raise to $65 (Buy) and a broader UBS upgrade of the healthcare sector — citing improving earnings revisions and biotech M&A tailwinds — have bolstered sentiment around the royalty model, with Q2 results now scheduled for August 5 acting as the next near-term catalyst.3.9425
July 16, 2026Royalty Pharma shares closed up modestly during the regular session and are surging in after-hours trading, gaining nearly 4%, as the company announced it will report Q2 2026 results on August 5. Investor sentiment is buoyed by TD Cowen's fresh price target raise to $65 and a broad analyst consensus of Buy, while UBS and State Street both upgraded their healthcare sector outlooks — a tailwind for biopharma royalty plays. The stock is approaching its 52-week high of $58.84 as institutional buying from Calamos Advisors and others offsets notable insider selling.1.1496
July 15, 2026Royalty Pharma closed modestly lower, underperforming a broadly positive session for the S&P 500, as healthcare sector headwinds weighed on sentiment. The XLV healthcare ETF also declined amid weakness in hospital operators like HCA Healthcare, which cut its profit forecast citing rising uninsured patients. On the positive side, State Street upgraded its healthcare sector outlook to positive for Q3 2026, citing expected earnings growth, and TD Cowen raised its price target on Royalty Pharma to $65 with a Buy rating — the latest in a string of analyst upgrades since the company's Q1 earnings beat. Notable insider selling activity, including over 427,000 shares sold by executives in the past 90 days, continues to temper near-term sentiment despite the broadly constructive analyst consensus.-1.3818
July 14, 2026Royalty Pharma closed essentially flat amid a broader market pullback driven by renewed U.S.-Iran tensions and surging oil prices, with the S&P 500 declining on the day. The defensive royalty model insulated RPRX from the worst of the selloff, and in after-hours trading the stock edged slightly higher. Investor sentiment remains constructive heading into Q2 earnings season, supported by a consensus Buy rating, recent price target increases from TD Cowen ($65), JPMorgan ($58), and Citigroup ($66), and a Zacks analysis noting the company's strong track record of earnings beats — most recently posting Q1 EPS of $1.30 vs. the $1.22 consensus.0.0354
July 11, 2026Royalty Pharma fell after pulling back from a recent all-time high of $58.02, as insider selling activity — totaling 427,800 shares worth ~$23.3 million over the past 90 days — weighed on sentiment, even as analysts remain broadly bullish ahead of Q2 earnings. The healthcare sector ETF (XLV) also closed lower, adding modest headwinds, while positive momentum signals and recent Russell 1000 Defensive index inclusion and a new $1.8B revolving credit facility continue to underpin the longer-term investment case.-2.6398
July 9, 2026Royalty Pharma edged modestly lower, closing just below the $58.37 prior close despite touching a new 52-week high of $58.84 intraday — reflecting the stock's remarkable run from a 52-week low of $34.08. The healthcare sector has been the standout performer in recent weeks, with XLV posting back-to-back weeks of outperformance over tech. Analyst sentiment remains broadly bullish, with Citigroup's $66 price target and Morgan Stanley's $63 overweight still well above current levels. A notable overhang is insider selling, with executives offloading over $23 million in shares over the past 90 days, even as institutional investors like Royal Bank of Canada and Y Intercept have been adding aggressively to positions.-0.7024
July 9, 2026Royalty Pharma closed modestly higher, brushing against its 52-week high of $58.55, as the healthcare sector outperformed a broader market weighed down by escalating U.S.-Iran tensions and rising oil prices. The stock continues to benefit from strong sector momentum — healthcare was the top-performing S&P 500 sector for the second consecutive week — and bullish analyst sentiment, with JPMorgan and Citigroup having recently raised price targets to $58 and $66, respectively. Investors are also tracking a funding deal worth up to $500 million with Teva Pharmaceuticals for TEV-'408, which is advancing to a Phase 2b vitiligo trial, while notable insider selling and a consensus analyst price target below current levels remain points of scrutiny.0.9862
MarketBeat · July 17, 2026Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month High - Here's Why↗Stock Titan · July 17, 2026Royalty Pharma dividend arrives Sept. 10 for Aug. 14 record-date holders↗Stock Titan · July 15, 2026Royalty Pharma schedules 8 a.m. webcast for Aug. 5 results↗Simply Wall Street · July 9, 2026Russell 1000 Defensive Inclusion Might Change The Case For Investing In Royalty Pharma (RPRX)↗ Mt Newswire · July 17, 2026Royalty Pharma Maintains Quarterly Dividend at $0.235 a Share, Payable on Sept. 10 to Shareholders of Record on Aug. 14Benzinga · July 13, 2026TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65Benzinga · July 7, 2026Teva Reports Early Skin Repigmentation Data, Sets Stage For Next TrialMt Newswire · June 25, 2026Royalty Pharma Insider Sold Shares Worth $8,159,277, According to a Recent SEC FilingMt Newswire · June 25, 2026Royalty Pharma Insider Sold Shares Worth $502,067, According to a Recent SEC FilingMt Newswire · May 28, 2026Royalty Pharma Insider Sold Shares Worth $3,476,116, According to a Recent SEC FilingBenzinga · May 7, 2026Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66Benzinga · May 6, 2026Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
